Don't Gamble On Antibodies
About 50% of the 6 million commercial antibodies fail basic characterization, driving billions in wasted experiments and irreproducible data (1-4).
Every mis-characterized and unvalidated antibody is a COIN FLIP with your reputation, funding and publication record on the line.
Tap Coin To Flip
Are you taking chances with your research?
The Scale Of The Antibody Crisis
Understanding where risk originates is only part of the solution. Programs that convert that awareness into structure connect validation, stability, reproducibility, and traceability within a continuous framework for decision-making that protects scientific integrity as discovery advances.
Only 1-2%
commercial antibodies fully comply with comprehensive, multi-pillar validation guidelines (5).
How To Improve Your Odds
If your current supplier cannot answer these questions, they are part of the antibody crisis and a liability to you.
We Are
The 1-2%
In a market flooded with under‑validated reagents, we are the statistical outlier – in a good way.
Most of the market treats characterization and validation as your problem, we engineer our antibodies so you avoid the coin‑flip.
Proven in the literature
Bethyl antibodies are cited in over 24,400 peer-reviewed publications and contribute to more than 300,000 citations across the Fortis portfolio, giving you real‑world, evidence you can trust.
Sequence–
Defined Identity
Recombinant antibodies, antigens, and VHHs are manufactured in‑house, ensuring consistent sourcing, controlled production, and reliable performance across lots and programs.
Chosen by Researchers
Bethyl, a Fortis company, received the 2021 CiteAb Researchers’ Choice Award, reflecting independent researcher preference for antibody performance and support.
Deep Characterization Data
Fortis reagents are characterized using biochemical and application-relevant biological assays to confirm specificity and performance consistency before release.
Six‑pillar
Validation
Antibodies are validated using the established Pillars of Antibody Validation and tested in application‑relevant assays, such as WB, IF/ICC, IHC, IP and ELISA), with each new lot evaluated to ensure consistent performance.
Farm to Bench Control
Vertically integrated farm‑to‑bench manufacturing, global distribution, and expert scientific support keep you connected to the original source, so quality and supply stay under control.
Antibodies That Shift Reproducibility in Your Favor
Bethyl Catalog Antibodies
Thousands of in-house manufactured mono‑ and polyclonal antibodies, validated in key application-relevant assays, giving you well-characterized reagents so you no longer have to piece together results from uncertain sources.
Primary antibodies, curated by biology
Secondary antibodies and conjugates
Recombinant monoclonals, monoclonals & polyclonals
Bethyl Custom Antibodies
Custom recombinant, monoclonal and polyclonal antibody development programs built on in-house antigen design, production, manufacturing and application-relevant validation, providing well-characterized reagents needed for high‑stakes studies.
- Design to hit - Antigen design, discovery, and screening performed in a fully integrated workflow, supported by in-house antigen production for high-quality custom antibody development.
- Built to fit - Custom monoclonal, polyclonal, VHH/single‑domain, and conjugated antibody formats to meet the performance needs of your specific assay or platform.
- Scale without disruption - Vertically integrated, US-based manufacturing ensures consistent continuity of supply.
AbNano VHH Single‑domain Programs
Immune‑derived VHH discovery and engineering performed end‑to‑end in‑house, delivering sequence‑defined single‑domain binders with full lineage traceability, supporting challenging targets and applications across diagnostics and next‑gen therapeutic discovery.
From Coin Toss to Defendable Data
We protect your most expensive experiments from antibody-driven failure.
Last year, a core facility we worked with lost weeks of imaging time when a commercial antibody from another vendor showed significant lot‑to‑lot variability mid‑grant. We provided the solution by rebuilding their panel with sequence‑defined reagents and application‑matched validation restoring their workflow and giving them results they could confidently defend.
Don’t take chances on your next antibody
Solid Phase Panning Package Grant Value
GRANT VALUE
-
Up to 3 rounds of panning with awardee-supplied recombinant protein targets adsorbed onto styrene plates
-
Single-point ELISA testing of 94 VHH from the output round
-
Comprehensive Sanger sequencing and delivery of hits
Solution Phase Panning Package Grant Value
GRANT VALUE
-
2 rounds of panning with biotin-labeled recombinant protein targets captured via streptavidin beads
-
Single-point ELISA testing of 188 VHH from the output round
-
Comprehensive Sanger sequencing and delivery of hits
- Baker, M. (2016). 1,500 scientists lift the lid on reproducibility. Nature, 533(7604), 452–454.
- National Academies of Sciences, Engineering, and Medicine. (2019). Reproducibility and replicability in science. National Academies Press.
- Kahn, R. A., & Laflamme, C. (2024). Antibody characterization is critical to enhance reproducibility in biomedical research. eLife, 13, e100211.
- Biddle, M., Stylianou, P., et al. (2024). Improving the integrity and reproducibility of research that uses antibodies: A technical, data sharing, behavioral and policy challenge. mAbs, 16(1), 2323706.
- Ayoubi, R., Laflamme, C., Shlaifer, I., et al. (2023). Scaling of an antibody validation procedure enables quantification of antibody performance at the proteome scale. eLife, 12, e91645.
